Research programme: anti-inflammatories - Avicenna

Drug Profile

Research programme: anti-inflammatories - Avicenna

Alternative Names: DAV0601

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Avicenna Pharma Development
  • Class
  • Mechanism of Action Sphingomyelin phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in United Arab Emirates (PO, Tablet)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Ulcerative-colitis in United Arab Emirates (PO, Tablet)
  • 31 Mar 2009 Preclinical trials in Inflammatory bowel disease in United Arab Emirates (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top